130 related articles for article (PubMed ID: 20148905)
1. Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin combination therapy.
Costelloe SJ; Wassef N; Schulz J; Vaghijiani T; Morris C; Whiting S; Thomas M; Dusheiko G; Jacobs M; Vanderpump MP
Clin Endocrinol (Oxf); 2010 Aug; 73(2):249-56. PubMed ID: 20148905
[TBL] [Abstract][Full Text] [Related]
2. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
[TBL] [Abstract][Full Text] [Related]
3. Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex.
Mammen JS; Ghazarian SR; Pulkstenis E; Subramanian GM; Rosen A; Ladenson PW
J Clin Endocrinol Metab; 2012 Sep; 97(9):3270-6. PubMed ID: 22689690
[TBL] [Abstract][Full Text] [Related]
4. Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010.
Barut S; Gunal O; Erkorkmaz U; Yildiz F
Braz J Infect Dis; 2012; 16(5):448-51. PubMed ID: 22964290
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
Chang YK; Tseng YT; Chen KH; Chen KT
BMC Endocr Disord; 2019 Apr; 19(1):36. PubMed ID: 30953492
[TBL] [Abstract][Full Text] [Related]
6. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis.
Kee KM; Lee CM; Wang JH; Tung HD; Changchien CS; Lu SN; Wang PW
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):319-26. PubMed ID: 16460494
[TBL] [Abstract][Full Text] [Related]
7. Interferon-induced thyroid dysfunction in chronic hepatitis C.
Jamil KM; Leedman PJ; Kontorinis N; Tarquinio L; Nazareth S; McInerney M; Connelly C; Flexman J; Burke V; Metcalf C; Cheng W
J Gastroenterol Hepatol; 2009 Jun; 24(6):1017-23. PubMed ID: 19054259
[TBL] [Abstract][Full Text] [Related]
8. Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C.
Nadeem A; Aslam M; Khan DA; Hussain T; Khan SA
J Coll Physicians Surg Pak; 2009 Feb; 19(2):86-9. PubMed ID: 19208310
[TBL] [Abstract][Full Text] [Related]
9. Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective.
Tran HA; Jones TL; Ianna EA; Foy A; Reeves GE
Endocr Pract; 2013; 19(2):292-300. PubMed ID: 23186968
[TBL] [Abstract][Full Text] [Related]
10. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
11. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.
Bini EJ; Mehandru S
Arch Intern Med; 2004 Nov; 164(21):2371-6. PubMed ID: 15557418
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis.
Tran HA; Attia JR; Jones TL; Batey RG
J Gastroenterol Hepatol; 2007 Apr; 22(4):472-6. PubMed ID: 17376035
[TBL] [Abstract][Full Text] [Related]
13. Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C.
Vasiliadis T; Anagnostis P; Nalmpantidis G; Soufleris K; Patsiaoura K; Grammatikos N; Orfanou-Koumerkeridou E; Kargiotis K; Slavakis A; Deliyiannidis A; Eugenidis N
Ann Acad Med Singap; 2011 Sep; 40(9):394-400. PubMed ID: 22065032
[TBL] [Abstract][Full Text] [Related]
14. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
[TBL] [Abstract][Full Text] [Related]
15. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?
Vezali E; Elefsiniotis I; Mihas C; Konstantinou E; Saroglou G
J Gastroenterol Hepatol; 2009 Jun; 24(6):1024-9. PubMed ID: 19383078
[TBL] [Abstract][Full Text] [Related]
16. Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy.
Andrade LJ; Atta AM; Atta ML; Mangabeira CN; Paraná R
Braz J Infect Dis; 2011; 15(4):377-81. PubMed ID: 21861010
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study.
Obołończyk Ł; Siekierska-Hellmann M; Wiśniewski P; Lewczuk A; Berendt-Obołończyk M; Lakomy A; Michalska Z; Radowska D; Moszkowska G; Bianek-Bodzak A; Sworczak K
Postepy Hig Med Dosw (Online); 2017 Sep; 71(0):842-849. PubMed ID: 29039351
[TBL] [Abstract][Full Text] [Related]
18. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.
Nguyen MH; Trinh HN; Garcia R; Nguyen G; Lam KD; Keeffe EB
Am J Gastroenterol; 2008 May; 103(5):1131-5. PubMed ID: 18477343
[TBL] [Abstract][Full Text] [Related]
19. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
Huang JF; Chuang WL; Dai CY; Chen SC; Lin ZY; Lee LP; Lee PL; Wang LY; Hsieh MY; Chang WY; Yu ML
J Viral Hepat; 2006 Jun; 13(6):396-401. PubMed ID: 16842442
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection.
Hung CH; Lee CM; Lu SN; Wang JH; Tung HD; Chen CH; Changchien CS
J Gastroenterol Hepatol; 2005 May; 20(5):727-32. PubMed ID: 15853986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
